Table 1 Clinical characteristics of patients with acute myocarditis/myopericarditis following COVID-19 vaccination
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
|---|---|---|---|---|---|
Age (years) | 22 | 19 | 25 | 37 | 20 |
Gender | Male | Male | Male | Male | Male |
Body mass index (kg/m2) | 24 | 25 | 28 | 28 | 26 |
Coronary artery disease risk factors | No | No | No | No | No |
Cardiac comorbidities | No | No | No | No | No |
Symptoms | |||||
Chest pain | Yes | Yes | Yes | Yes | Yes |
Dyspnea | No | Yes | Yes | No | Yes |
Other | Headache, generalized malaise | Nausea, emesis | Generalized body aches, nausea, headache, chills, and fatigue | Fever, diaphoresis, rigors, nausea, myalgia, headache, fatigue | Headache, body ache |
Arrhythmia | No | No | No | No | No |
COVID-19 vaccine doses prior to symptom onset | 1 | 2 | 2 | 2 | 2 |
COVID-19 vaccine manufacturer | Pfizer | Pfizer | Moderna | Pfizer | Pfizer |
Days after vaccine administration prior to symptom onset | 2 | 1 | 3 | 2 | 3 |
Cardiac rub | No | No | No | No | No |
Serum TnI (ng/ml) | 37 | 49 | 17 | 26 | 58 |
Brain natriuretic peptide (pg/ml) | Not obtained | Not obtained | Not obtained | Not obtained | 133 |
Erythrocyte sedimentation rate (mm/hr) | Not obtained | 26 | 24 | 32 | 20 |
C-reactive protein (mg/l) | 50 | 109 | 96 | Not obtained | Not obtained |
SARS COVID-19 PCR testing | Negative | Negative | Negative | Negative | Negative |
Other Viral Serologies | |||||
Adenovirus | Not detected | Not detected | Not detected | Not obtained | Not detected |
Coxsackie antibody | Not obtained | Not detected | Not obtained | Not obtained | Negative |
Echovirus Titer | Not obtained | Not obtained | Not obtained | Negative | |
Rhinovirus | Not detected | Not detected | Not detected | Not obtained | Not detected |
Influenza/ Parainfluenza | Not detected | Not detected | Not detected | Not detected | Not detected |
Parvovirus B19 | Not obtained | Not detected | Not obtained | Not obtained | Not detected |
Respiratory Syncytial Virus | Not detected | Not detected | Not detected | Not detected | Not detected |
Epstein-Barr Virus | Not obtained | Not detected | Not obtained | Not obtained | Not obtained |
Bacterial test | |||||
Lyme antibodies | Negative | Not detected | Not obtained | Negative | Negative |
Mycoplasma pneumoniae | Not detected | Not detected | Not detected | Not obtained | Not detected |
Chlamydia pneumoniae | Not detected | Not detected | Not detected | Not obtained | Not detected |
TTE LVEF (%) | 55 | 62 | 60 | 65 | 51 |
CMR LVEF (%) | 65 | 59 | 59 | 61 | 59 |
TTE Global longitudinal strain (%) | − 19.0 | − 12.0 | − 21.0 | − 18.0 | − 14.0 |
CMR Global longitudinal strain (%) | − 19.1 | − 12.1 | − 19.6 | − 16.0 | − 12.2 |
Pericardial effusion | No | No | No | No | No |
Anatomic coronary artery assessment | Non-obstructive (ICA) | Not obtained | Not obtained | Non-obstructive (ICA) | Non-obstructive (CCTA) |
Oxygen support | No | No | No | No | No |
Length of stay (days) | 2 | 2 | 1 | 2 | 2 |
Death | No | No | No | No | No |
Discharge medications | High-dose aspirin, colchicine | Colchicine, high-dose ibuprofen | Colchicine | None | Colchicine, high-dose ibuprofen, lisinopril, metoprolol tartrate |